Lucid Diagnostics Stock Performance
| LUCD Stock | USD 1.13 0.02 1.80% |
Lucid Diagnostics has a performance score of 1 on a scale of 0 to 100. The company secures a Beta (Market Risk) of 1.63, which conveys a somewhat significant risk relative to the market. As the market goes up, the company is expected to outperform it. However, if the market returns are negative, Lucid Diagnostics will likely underperform. Lucid Diagnostics right now secures a risk of 3.48%. Please verify Lucid Diagnostics coefficient of variation, maximum drawdown, skewness, as well as the relationship between the total risk alpha and downside variance , to decide if Lucid Diagnostics will be following its current price movements.
Risk-Adjusted Performance
Weak
Weak | Strong |
Compared to the overall equity markets, risk-adjusted returns on investments in Lucid Diagnostics are ranked lower than 1 (%) of all global equities and portfolios over the last 90 days. In spite of rather sound fundamental indicators, Lucid Diagnostics is not utilizing all of its potentials. The latest stock price tumult, may contribute to shorter-term losses for the shareholders. ...more
1 | Acquisition by Palumbo John R of 215000 shares of Lucid Diagnostics at 1.03 subject to Rule 16b-3 | 10/06/2025 |
2 | Is Lucid Diagnostics Inc. trending in predictive chart models - IPO Watch Accurate Entry and Exit Point Alerts - newser.com | 10/13/2025 |
3 | Will Lucid Diagnostics Inc. stock maintain momentum in 2025 - Earnings Growth Report Stepwise Swing Trade Plans - newser.com | 10/31/2025 |
4 | Will Lucid Diagnostics Inc. stock continue dividend increases - Portfolio Update Report Weekly High Potential Stock Alerts - newser.com | 11/04/2025 |
5 | Sensus Healthcare, Inc. Reports Q3 Loss, Tops Revenue Estimates | 11/06/2025 |
6 | Lucid Diagnostics Inc Q3 2025 Earnings Report Preview What To Look For | 11/11/2025 |
7 | Lucid Diagnostics Inc. Q3 2025 Earnings Call Transcript | 11/13/2025 |
8 | Lucid Diagnostics stock maintains Overweight rating at Cantor Fitzgerald - Investing.com | 11/19/2025 |
9 | Lucid Diagnostics stock falls after pricing capital raise of 15M via stock offering - MSN | 12/01/2025 |
10 | Lucid Diagnostics Announces Positive Data from the Largest Reported Real-World Experience of Esophageal Precancer Detection | 12/09/2025 |
| Begin Period Cash Flow | 18.9 M | |
| Total Cashflows From Investing Activities | -646 K | |
| Free Cash Flow | -44.8 M |
Lucid Diagnostics Relative Risk vs. Return Landscape
If you would invest 109.00 in Lucid Diagnostics on September 19, 2025 and sell it today you would earn a total of 2.00 from holding Lucid Diagnostics or generate 1.83% return on investment over 90 days. Lucid Diagnostics is currently generating 0.0864% in daily expected returns and assumes 3.483% risk (volatility on return distribution) over the 90 days horizon. In different words, 31% of stocks are less volatile than Lucid, and 99% of all traded equity instruments are projected to make higher returns than the company over the 90 days investment horizon. Expected Return |
| Risk |
Lucid Diagnostics Market Risk Analysis
Today, many novice investors tend to focus exclusively on investment returns with little concern for Lucid Diagnostics' investment risk. Standard deviation is the most common way to measure market volatility of stocks, such as Lucid Diagnostics, and traders can use it to determine the average amount a Lucid Diagnostics' price has deviated from the expected return over a period of time. It is calculated by determining the expected price for the established period and then subtracting this figure from each price point. The differences are then squared, summed, and averaged to produce the variance.
Sharpe Ratio = 0.0248
| Best Portfolio | Best Equity | |||
| Good Returns | ||||
| Average Returns | ||||
| Small Returns | ||||
| Cash | Small Risk | Average Risk | LUCD | Huge Risk |
| Negative Returns |
Based on monthly moving average Lucid Diagnostics is performing at about 1% of its full potential. If added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of Lucid Diagnostics by adding it to a well-diversified portfolio.
Lucid Diagnostics Fundamentals Growth
Lucid Stock prices reflect investors' perceptions of the future prospects and financial health of Lucid Diagnostics, and Lucid Diagnostics fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on Lucid Stock performance.
| Return On Equity | -3.31 | ||||
| Return On Asset | -0.79 | ||||
| Operating Margin | (9.71) % | ||||
| Current Valuation | 177.45 M | ||||
| Shares Outstanding | 131.1 M | ||||
| Price To Book | 2.16 X | ||||
| Price To Sales | 33.08 X | ||||
| Revenue | 4.35 M | ||||
| Gross Profit | (2.56 M) | ||||
| EBITDA | (44.34 M) | ||||
| Net Income | (45.53 M) | ||||
| Cash And Equivalents | 34.46 M | ||||
| Cash Per Share | 0.89 X | ||||
| Total Debt | 21.25 M | ||||
| Debt To Equity | 0.06 % | ||||
| Current Ratio | 4.55 X | ||||
| Book Value Per Share | (0.23) X | ||||
| Cash Flow From Operations | (44.14 M) | ||||
| Earnings Per Share | (0.77) X | ||||
| Market Capitalization | 145.52 M | ||||
| Total Asset | 30.71 M | ||||
| Retained Earnings | (203.77 M) | ||||
| Working Capital | 1.62 M | ||||
About Lucid Diagnostics Performance
By analyzing Lucid Diagnostics' fundamental ratios, stakeholders can gain valuable insights into Lucid Diagnostics' financial health, operational efficiency, and overall profitability, helping them make informed investment and management decisions. For instance, if Lucid Diagnostics has a high ROA and ROE, it suggests that the company is efficiently using its assets and equity to generate substantial profits, making it an attractive investment. Conversely, if Lucid Diagnostics has a low ROA and ROE, it may indicate underlying issues in asset and equity management, signaling a need for operational improvements.
| Last Reported | Projected for Next Year | ||
| Days Of Inventory On Hand | 15.06 | 14.30 | |
| Return On Tangible Assets | (1.52) | (1.59) | |
| Return On Capital Employed | (6.40) | (6.08) | |
| Return On Assets | (1.48) | (1.56) | |
| Return On Equity | (8.45) | (8.02) |
Things to note about Lucid Diagnostics performance evaluation
Checking the ongoing alerts about Lucid Diagnostics for important developments is a great way to find new opportunities for your next move. Stock alerts and notifications screener for Lucid Diagnostics help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| Lucid Diagnostics may become a speculative penny stock | |
| Lucid Diagnostics had very high historical volatility over the last 90 days | |
| Lucid Diagnostics has a very high chance of going through financial distress in the upcoming years | |
| The company reported the previous year's revenue of 4.35 M. Net Loss for the year was (45.53 M) with loss before overhead, payroll, taxes, and interest of (2.56 M). | |
| Lucid Diagnostics currently holds about 34.46 M in cash with (44.14 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 0.89. | |
| Roughly 35.0% of the company outstanding shares are owned by corporate insiders | |
| Latest headline from finance.yahoo.com: Lucid Diagnostics Announces Positive Data from the Largest Reported Real-World Experience of Esophageal Precancer Detection |
- Analyzing Lucid Diagnostics' financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether Lucid Diagnostics' stock is overvalued or undervalued compared to its peers.
- Examining Lucid Diagnostics' industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating Lucid Diagnostics' management team can have a significant impact on its success or failure. Reviewing the track record and experience of Lucid Diagnostics' management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of Lucid Diagnostics' stock. These opinions can provide insight into Lucid Diagnostics' potential for growth and whether the stock is currently undervalued or overvalued.
Complementary Tools for Lucid Stock analysis
When running Lucid Diagnostics' price analysis, check to measure Lucid Diagnostics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Lucid Diagnostics is operating at the current time. Most of Lucid Diagnostics' value examination focuses on studying past and present price action to predict the probability of Lucid Diagnostics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Lucid Diagnostics' price. Additionally, you may evaluate how the addition of Lucid Diagnostics to your portfolios can decrease your overall portfolio volatility.
| Latest Portfolios Quick portfolio dashboard that showcases your latest portfolios | |
| Watchlist Optimization Optimize watchlists to build efficient portfolios or rebalance existing positions based on the mean-variance optimization algorithm |